Shigeo Takahashi1,2, Yuji Murakami3, Nobuki Imano3, Yuko Kaneyasu3,4, Yoshiko Doi3, Masahiro Kenjo3, Tomoki Kimura3, Takayuki Kadoya5,6, Koji Arihiro7, Tsuyoshi Kataoka5, Morihito Okada5,6, Yasushi Nagata3. 1. Department of Radiation Oncology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. shigeot@med.kagawa-u.ac.jp. 2. Department of Radiation Oncology, Kagawa University Hospital, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. shigeot@med.kagawa-u.ac.jp. 3. Department of Radiation Oncology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. 4. Department of Radiotherapy, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan. 5. Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. 6. Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. 7. Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
Abstract
PURPOSE: The long-term outcomes of whole-breast and boost irradiation after breast-conserving surgery (BCS) for patients with breast cancer were retrospectively analyzed. MATERIALS AND METHODS: Patients who received whole-breast and boost irradiation after BCS from 1990 to 2002 were included. Boost irradiation was administered to each tumor bed, regardless of the surgical margin status. The median doses of whole-breast and boost irradiation were 45 Gy in 25 fractions (range 36-45 Gy), and 14 Gy in 7 fractions (range 0-14 Gy), respectively. RESULTS: Data for 306 patients were analyzed. With a median follow-up time of 144 months, the 10-year overall survival, disease-free survival, ipsilateral breast tumor recurrence (IBTR), and metachronous contralateral breast cancer (MCBC) occurrence rates were 93.0, 84.1, 2.1, and 4.1 %, respectively. In the multivariate analysis, pT2 was a significant risk factor for IBTR (p = 0.041), while age ≤ 50 years and pT2 were significant risk factors for MCBC occurrence (p = 0.003 and 0.043, respectively). One patient (0.3 %) developed angiosarcoma in the irradiated region 120 months after the completion of radiation therapy. CONCLUSION: The 12-year outcome of breast-conserving therapy using whole-breast and boost irradiation with doses of 45 and 14 Gy, respectively, was favorable.
PURPOSE: The long-term outcomes of whole-breast and boost irradiation after breast-conserving surgery (BCS) for patients with breast cancer were retrospectively analyzed. MATERIALS AND METHODS:Patients who received whole-breast and boost irradiation after BCS from 1990 to 2002 were included. Boost irradiation was administered to each tumor bed, regardless of the surgical margin status. The median doses of whole-breast and boost irradiation were 45 Gy in 25 fractions (range 36-45 Gy), and 14 Gy in 7 fractions (range 0-14 Gy), respectively. RESULTS: Data for 306 patients were analyzed. With a median follow-up time of 144 months, the 10-year overall survival, disease-free survival, ipsilateral breast tumor recurrence (IBTR), and metachronous contralateral breast cancer (MCBC) occurrence rates were 93.0, 84.1, 2.1, and 4.1 %, respectively. In the multivariate analysis, pT2 was a significant risk factor for IBTR (p = 0.041), while age ≤ 50 years and pT2 were significant risk factors for MCBC occurrence (p = 0.003 and 0.043, respectively). One patient (0.3 %) developed angiosarcoma in the irradiated region 120 months after the completion of radiation therapy. CONCLUSION: The 12-year outcome of breast-conserving therapy using whole-breast and boost irradiation with doses of 45 and 14 Gy, respectively, was favorable.
Authors: Bas Kreike; Augustinus A M Hart; Tony van de Velde; Jacques Borger; Hans Peterse; Emiel Rutgers; Harry Bartelink; Marc J van de Vijver Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-30 Impact factor: 7.038
Authors: Voralak Vichapat; Cheryl Gillett; Ian S Fentiman; Andrew Tutt; Lars Holmberg; Margreet Lüchtenborg Journal: Eur J Cancer Date: 2011-06-12 Impact factor: 9.162
Authors: Nils D Arvold; Alphonse G Taghian; Andrzej Niemierko; Rita F Abi Raad; Meera Sreedhara; Paul L Nguyen; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris Journal: J Clin Oncol Date: 2011-09-06 Impact factor: 44.544
Authors: Harry Bartelink; Philippe Maingon; Philip Poortmans; Caroline Weltens; Alain Fourquet; Jos Jager; Dominic Schinagl; Bing Oei; Carla Rodenhuis; Jean-Claude Horiot; Henk Struikmans; Erik Van Limbergen; Youlia Kirova; Paula Elkhuizen; Rudolf Bongartz; Raymond Miralbell; David Morgan; Jean-Bernard Dubois; Vincent Remouchamps; René-Olivier Mirimanoff; Sandra Collette; Laurence Collette Journal: Lancet Oncol Date: 2014-12-09 Impact factor: 41.316
Authors: Philip M Poortmans; Laurence Collette; Jean-Claude Horiot; Walter F Van den Bogaert; Alain Fourquet; Abraham Kuten; Evert M Noordijk; Willem Hoogenraad; René-Olivier Mirimanoff; Marianne Pierart; Erik Van Limbergen; Harry Bartelink Journal: Radiother Oncol Date: 2008-08-15 Impact factor: 6.280
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321